HONG KONG-KPMG China recently led a delegation of Chinese biotech companies’ C-suite executives to explore opportunities in the rapidly developing APAC/ASEAN market.
The APAC/ASEAN region has emerged as a crucial destination for global biotech expansion, fuelled by the robust collaboration between China and APAC/ASEAN through the Belt and Road Initiative.
This venture follows KPMG China’s successful exploration of the Mid-East forum in May 2023.
During the six-day on-site forum from 4th – 9th December, 20 C-suite executives from Chinese biotech companies visited prominent institutions in Singapore and Indonesia, including the Singapore Economic Development Board (EDB), Agency for Science, Technology and Research (A*STAR), Garea technology, Rxilient Health Pte. Ltd. (Rxilient), DBS Bank, China International Capital Corporation (CICC), China-Singapore Suzhou Industrial Park Development, Indonesia’s Ministry of Health (MoH), PT Etana Biotechnologies Indonesia (Etana), medical technology company UBC, Tigermed, CFLD, etc.
Komentari tentang post ini